Biocon nears full integration of biologics business after Mylan buyback
The Bengaluru-based company on 14 January said it raised $460 million via a QIP of shares to buy out Mylan Inc’s (Viatris) stake in its arm Biocon Biologics. Days later, it announced the acquisition of the remaining shares from Mylan for $200 million.
The Bengaluru-based company on 14 January said it raised $460 million via a QIP of shares to buy out Mylan Inc’s (Viatris) stake in its arm Biocon Biologics. Days later, it announced the acquisition of the remaining shares from Mylan for $200 million.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
